加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.5702
+US$0.0102 · +1.82%
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
前收盘价
US$0.5702
+US$0.0102 · +1.82%
盘中时间采用ET。市场数据可能有所延迟。
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
日内区间
当前US$0.5702
52周区间
当前US$0.5702
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
44
合理估值
情绪
57
多空交织
风险
90
极高风险
动量
25
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
日内区间
当前US$0.5702
52周区间
当前US$0.5702
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 105.6万 USD | — | — | — | — |
| 毛利 | −105.6万 USD | — | — | — | — |
| 研究与开发 | 6051.8万 USD | 5582.1万 USD | 5178.5万 USD | 3462.7万 USD | 2542.1万 USD |
| 销售、一般及管理费用 | 1894.4万 USD | 2041.8万 USD | 1707.6万 USD | 1656.9万 USD | 1141.2万 USD |
| 营业费用 | 7946.2万 USD | 7623.9万 USD | 6886.1万 USD | 5119.6万 USD | 3683.3万 USD |
| 利息收入 | 174.1万 USD | 505.8万 USD | 519.9万 USD | 70.1万 USD | — |
| 折旧和摊销 | 105.6万 USD | 137.3万 USD | 110.8万 USD | 97.5万 USD | 37.7万 USD |
| 营业利润 | −8051.8万 USD | −7623.9万 USD | −6886.1万 USD | −5119.6万 USD | −3683.3万 USD |
| 净利润 | −7580.1万 USD | −7126.9万 USD | −6446.5万 USD | −3768.5万 USD | −3063.7万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$2.50
上涨空间 338.44%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年1月4日 | 1:10 | — | — |
已生效 2024年1月4日
1:10
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
